drugset / Trial / NCT01889095
Biphasic Insulin Aspart Versus NPH Plus Regular Human Insulin in Type 2 Diabetic Patients
RandomizedParallel-groupSingle-blindTreatment
Summary
Glycemic control is fundamental in the management of diabetes mellitus .If lifestyle intervention and full tolerated doses of one or two oral glucose lowering drugs (OGLDs) fail to achieve or sustain glycemic goals, insulin should be initiated. New insulin analogs are generated to improve glycemic control .New insulin analogs are generated to improve glycemic control,However, the cost of these analogs is a major problem .The aim of this piggy back evaluation was to assess the effect of BIAsp 30 versus NPH plus regular human insulin on metabolic control as well as its cost-effectiveness in people with type 2 diabetes in the Iranian setting.
Timeline
- Start
- 2011-07
- Primary completion
- 2011-08
- Completion
- 2012-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BIAsp 30 | Unknown | 0.2 iu/kg | — |
| Subject | BIAsp 30 | Unknown | 0.6 iu/kg | — |
| Comparator | NPH/Reg | Unknown | 0.2 iu/kg | — |
| Comparator | NPH/Reg | Unknown | 0.6 iu/kg | — |